Olema Oncology to Present at Two Upcoming Investor Conferences

Rhea-AI Summary

Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on women's cancers, announced participation in two investor conferences this November. The events include the Jefferies London Healthcare Conference on November 16, 2021, at 5:00 p.m. GMT, and the 4th Annual Evercore ISI HealthCONx Conference on November 30, 2021, at 11:45 a.m. ET. Live webcasts will be available on Olema’s website and archived for 14 days. Olema’s lead product, OP-1250, targets ER-positive breast cancer and is currently undergoing clinical trials.

SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that management will participate in two upcoming investor conferences in November.

Details for the company’s participation are as follows:

• Event: Jefferies London Healthcare Conference
  Date: Tuesday, November 16, 2021
  Time: 5:00 p.m. GMT (12:00 p.m. ET / 9:00 a.m. PT)
  Format: Live Fireside Chat
• Event: 4th Annual Evercore ISI HealthCONx Conference
  Date: Tuesday, November 30, 2021
  Time: 11:45 a.m. ET (8:45 a.m. PT)
  Format: Live Fireside Chat

Live webcasts of these presentations may be accessed under the Investors & Media section of Olema’s website (www.olema.com) and will be archived for 14 days.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is based in San Francisco and has operations in Cambridge, Massachusetts.

Contact:
Eva Stroynowski
Vice President, Communications and Investor Relations
eva@olema.com

FAQ

What conferences is Olema Pharmaceuticals participating in November 2021?

Olema Pharmaceuticals will participate in the Jefferies London Healthcare Conference on November 16 and the 4th Annual Evercore ISI HealthCONx Conference on November 30, 2021.

What time is the Jefferies London Healthcare Conference?

The Jefferies London Healthcare Conference is scheduled for November 16, 2021, at 5:00 p.m. GMT.

What is Olema's lead product candidate?

Olema's lead product candidate is OP-1250, which targets estrogen receptor-positive breast cancer.

Where can I watch the live webcasts of Olema's investor presentations?

Live webcasts of Olema's presentations can be accessed on their website under the Investors & Media section.

How long will the webcasts of Olema's presentations be available?

The webcasts will be archived for 14 days after the presentations.